Switch theme
Sign up to access all valuation multiples
Sinocare Inc operates in the healthcare industry. It is engaged in the development, manufacturing, and marketing of diagnosis testing products for people with chronic diseases and healthcare professionals. Its product range covers household blood glucose meter, medical blood glucose meter, urinary microalbumin test strip and blood lipid uric acid products. In addition, the company also provides diabetes management information systems.
2002
n/a
LTM Revenue $622M
LTM EBITDA $91.7M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sinocare has a last 12-month revenue of $622M and a last 12-month EBITDA of $91.7M.
In the most recent fiscal year, Sinocare achieved revenue of $559M and an EBITDA of $71.6M.
Sinocare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sinocare valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $559M | $601M | XXX | XXX | XXX |
| Gross Profit | $195M | $228M | XXX | XXX | XXX |
| Gross Margin | 35% | 38% | XXX | XXX | XXX |
| EBITDA | $71.6M | $86.9M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 14% | XXX | XXX | XXX |
| Net Profit | $14.8M | $59.4M | XXX | XXX | XXX |
| Net Margin | 3% | 10% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sinocare's stock price is CNY 21 (or $3).
Sinocare has current market cap of CNY 11.9B (or $1.6B), and EV of CNY 12.0B (or $1.7B).
See Sinocare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.6B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sinocare has market cap of $1.6B and EV of $1.7B.
Sinocare's trades at 2.7x LTM EV/Revenue multiple, and 18.1x LTM EBITDA.
Analysts estimate Sinocare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sinocare and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 19.1x | XXX | XXX | XXX |
| P/E | 33.7x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSinocare's NTM/LTM revenue growth is 12%
Sinocare's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Sinocare's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sinocare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sinocare and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 27% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sinocare acquired XXX companies to date.
Last acquisition by Sinocare was XXXXXXXX, XXXXX XXXXX XXXXXX . Sinocare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sinocare founded? | Sinocare was founded in 2002. |
| Where is Sinocare headquartered? | Sinocare is headquartered in China. |
| Is Sinocare publicy listed? | Yes, Sinocare is a public company listed on SHE. |
| What is the stock symbol of Sinocare? | Sinocare trades under 300298 ticker. |
| When did Sinocare go public? | Sinocare went public in 2012. |
| Who are competitors of Sinocare? | Similar companies to Sinocare include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sinocare? | Sinocare's current market cap is $1.6B |
| What is the current revenue of Sinocare? | Sinocare's last 12-month revenue is $622M. |
| What is the current EBITDA of Sinocare? | Sinocare's last 12-month EBITDA is $91.7M. |
| What is the current EV/Revenue multiple of Sinocare? | Current revenue multiple of Sinocare is 2.7x. |
| What is the current EV/EBITDA multiple of Sinocare? | Current EBITDA multiple of Sinocare is 18.1x. |
| What is the current revenue growth of Sinocare? | Sinocare revenue growth between 2023 and 2024 was 7%. |
| Is Sinocare profitable? | Yes, Sinocare is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
